Rationale for assessing the therapeutic potential of resveratrol in hematological malignancies

Promising results from pre-clinical studies on the naturally-occurring polyphenol resveratrol have generated considerable interest and somewhat excessive expectations regarding the therapeutic potential of this compound for treating or preventing various diseases, including cardiovascular and neurod...

Full description

Saved in:
Bibliographic Details
Published in:Blood reviews 2019-01, Vol.33, p.43-52
Main Authors: Espinoza, J. Luis, Kurokawa, Yu, Takami, Akiyoshi
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents, Phytogenic - pharmacology
Antineoplastic Agents, Phytogenic - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cell purging
Clinical Trials as Topic
Drug Evaluation, Preclinical
Drug Interactions
Hematologic Neoplasms - diagnosis
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - etiology
Hematologic Neoplasms - mortality
Herpesvirus 4, Human - physiology
Humans
Immunocompromised Host
Myeloproliferative disorders
Post-transplant lymphoproliferative
Resveratrol
Resveratrol - pharmacology
Resveratrol - therapeutic use
Treatment Outcome
Virus Activation - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Promising results from pre-clinical studies on the naturally-occurring polyphenol resveratrol have generated considerable interest and somewhat excessive expectations regarding the therapeutic potential of this compound for treating or preventing various diseases, including cardiovascular and neurodegenerative disorders and cancer. Resveratrol has potent inhibitory activity in vitro against various tumor types, including cell lines derived from virtually all blood malignancies. Pharmacological studies have shown that resveratrol is safe for humans but has poor bioavailability, due to its extensive hepatic metabolism. Curiously, a substantial proportion of the orally administered resveratrol can reach the bone marrow compartment. Notably, various pathways dysregulated in blood cancers are known to be molecular targets of resveratrol, thus substantiating the potential utility of this agent in blood malignancies. In this review, we primarily focus on the scientific evidence that supports the potential utility of resveratrol for the management of select hematological malignancies. In addition, potential clinical trials with resveratrol are suggested.
ISSN:0268-960X
1532-1681
DOI:10.1016/j.blre.2018.07.001